XML 35 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2017
USD ($)
PerformanceObligation
May 31, 2015
USD ($)
Mar. 31, 2019
USD ($)
PerformanceObligation
Dec. 31, 2018
USD ($)
Jun. 30, 2018
Agreement
Mar. 31, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2018
USD ($)
Revenue Recognition [Abstract]                
Number of performance obligations at inception of contract | PerformanceObligation     1          
Revenue     $ 297,214     $ 144,419    
Biogen [Member]                
Revenue Recognition [Abstract]                
Number of agreements | Agreement         2      
Licensing and Other Royalty Revenue [Member]                
Revenue Recognition [Abstract]                
Revenue     1,623     $ 942    
Roche [Member] | IONIS-HTT [Member]                
Revenue Recognition [Abstract]                
Revenue     35,000         $ 0
IONIS-FB-L for Complement-Mediated Diseases [Member]                
Revenue Recognition [Abstract]                
Upfront payment received       $ 75,000        
Neurology [Member]                
Revenue Recognition [Abstract]                
Milestone payment earned and amortized over period of performance             $ 10,000  
Novartis [Member] | Licensing and Other Royalty Revenue [Member]                
Revenue Recognition [Abstract]                
Revenue     $ 150,000          
Bayer [Member]                
Revenue Recognition [Abstract]                
Number of separate performance obligations | PerformanceObligation 3              
Bayer [Member]                
Revenue Recognition [Abstract]                
Upfront payment received   $ 100,000            
Bayer [Member]                
Revenue Recognition [Abstract]                
Upfront payment received $ 75,000              
Transaction price $ 75,000